Wed, November 24, 2010
Tue, November 23, 2010
Mon, November 22, 2010
Sat, November 20, 2010
Fri, November 19, 2010
Thu, November 18, 2010
Wed, November 17, 2010
Tue, November 16, 2010
Mon, November 15, 2010
Sun, November 14, 2010
Fri, November 12, 2010
Thu, November 11, 2010
Wed, November 10, 2010
Tue, November 9, 2010
Mon, November 8, 2010
Sun, November 7, 2010
Sat, November 6, 2010
Fri, November 5, 2010
Thu, November 4, 2010

Cerus to Present at the Lazard Capital Markets 7th Annual Healthcare Conference


//health-fitness.news-articles.net/content/2010/ .. al-markets-7th-annual-healthcare-conference.html
Published in Health and Fitness on Friday, November 12th 2010 at 5:49 GMT by Market Wire   Print publication without navigation


CONCORD, Calif.--([ BUSINESS WIRE ])--Cerus Corporation (NASDAQ:CERS) announced today that Laurence Corash, M.D., senior vice president and chief medical officer, is scheduled to present a corporate update at the Lazard Capital Markets 7th Annual Healthcare Conference on Tuesday, November 16, 2010 at 2:10pm EST. The conference will be held at The St. Regis Hotel in New York, New York.

A live webcast of the presentation will be available from the Investor Relations page of the Cerus web site at [ http://investor.cerus.com ]. A replay will be available for approximately two weeks following the completion of the event.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See [ http://www.cerus.com ] for more information.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.


Publication Contributing Sources